The Hidden Link Between HIV and Cardiomyopathy: Unraveling HIV’s Impact on the Heart

For years, human immunodeficiency virus (HIV) was considered primarily an immunological threat. However, advancements in HIV treatment have dramatically increased life expectancy for those living with the virus, revealing a growing concern: an increased risk of cardiovascular disease, particularly cardiomyopathy. This review explores the complex relationship between HIV and cardiomyopathy, examining the underlying mechanisms, clinical presentations, diagnostic approaches, and potential treatment strategies.

Understanding HIV-Associated Cardiomyopathy

Cardiomyopathy refers to diseases of the heart muscle that make it harder for the heart to pump blood. In individuals with HIV, cardiomyopathy can develop through several pathways. The prevalence of cardiac involvement in people with AIDS has been reported to range from 28% to 73% ¹. The longer survival rates achieved through antiretroviral therapy have allowed for the emergence of these long-term cardiovascular complications.

Pathogenesis: How HIV Impacts the Heart

The development of cardiomyopathy in HIV-positive individuals is multifaceted. Direct HIV infection of cardiac cells, chronic inflammation, and immune dysregulation all contribute to the disease process. Recent research has deepened our understanding of the pathogenesis of HIV-associated cardiovascular disease ². Certain antiretroviral therapies themselves can have cardiotoxic effects, adding another layer of complexity.

Clinical Manifestations

HIV-associated cardiomyopathy can present with a range of symptoms, including:

• Shortness of breath
• Fatigue
• Swelling in the ankles and feet
• Irregular heartbeat
• Chest pain

However, many individuals may be asymptomatic, making early detection challenging.

Diagnosis

Diagnosing HIV-associated cardiomyopathy requires a comprehensive evaluation, including:

• Echocardiogram: An ultrasound of the heart to assess its structure and function.
• Electrocardiogram (ECG): To detect abnormal heart rhythms.
• Cardiac Magnetic Resonance Imaging (MRI): Provides detailed images of the heart muscle.
• Biomarkers: Blood tests to measure cardiac enzymes and other indicators of heart damage.

Treatment Strategies

Management of HIV-associated cardiomyopathy involves a combination of approaches:

• Antiretroviral Therapy (ART): Suppressing HIV replication is crucial to reduce inflammation and viral load.
• Heart Failure Medications: Including ACE inhibitors, beta-blockers, and diuretics, to manage symptoms and improve heart function.
• Lifestyle Modifications: Such as a heart-healthy diet, regular exercise, and smoking cessation.

The Evolving Landscape of HIV and Cardiovascular Health

As the HIV population continues to age and live longer, the incidence of cardiovascular complications, including cardiomyopathy, is expected to rise. A recent review highlights the valuable insights gained for clinicians and researchers in infectious diseases and cardiology ³. Continued research is essential to develop more effective prevention and treatment strategies, ultimately improving the cardiovascular health and quality of life for individuals living with HIV. The improved life expectancy of individuals with HIV has shifted the focus to the long-term impact of the virus on cardiovascular health ⁴.